Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

270 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Renal cell cancer: overview of the current therapeutic landscape.
Erman M, Benekli M, Basaran M, Bavbek S, Buyukberber S, Coskun U, Demir G, Karabulut B, Oksuzoglu B, Ozkan M, Sevinc A, Yalcin S. Erman M, et al. Expert Rev Anticancer Ther. 2016 Sep;16(9):955-68. doi: 10.1080/14737140.2016.1222908. Epub 2016 Aug 24. Expert Rev Anticancer Ther. 2016. PMID: 27548347 Review.
Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.
Levy B, Paz-Ares L, Bennouna J, Felip E, Abreu DR, Isla D, Barlesi F, Molinier O, Madelaine J, Audigier-Valette C, Kim SW, Kim HR, Ozguroglu M, Erman M, Badin FB, Mekhail TM, Scheff R, Chisamore MJ, Sadrolhefazi B, Riess JW. Levy B, et al. Among authors: erman m. Clin Lung Cancer. 2019 May;20(3):e407-e412. doi: 10.1016/j.cllc.2018.12.022. Epub 2019 Jan 4. Clin Lung Cancer. 2019. PMID: 30808583 Free article.
PILE: a candidate prognostic score in cancer patients treated with immunotherapy.
Guven DC, Yildirim HC, Bilgin E, Aktepe OH, Taban H, Sahin TK, Cakir IY, Akin S, Dizdar O, Aksoy S, Yalcin S, Erman M, Kilickap S. Guven DC, et al. Among authors: erman m. Clin Transl Oncol. 2021 Aug;23(8):1630-1636. doi: 10.1007/s12094-021-02560-6. Epub 2021 Feb 14. Clin Transl Oncol. 2021. PMID: 33586122
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.
Blackhall F, Jao K, Greillier L, Cho BC, Penkov K, Reguart N, Majem M, Nackaerts K, Syrigos K, Hansen K, Schuette W, Cetnar J, Cappuzzo F, Okamoto I, Erman M, Langer SW, Kato T, Groen H, Sun Z, Luo Y, Tanwani P, Caffrey L, Komarnitsky P, Reinmuth N. Blackhall F, et al. Among authors: erman m. J Thorac Oncol. 2021 Sep;16(9):1547-1558. doi: 10.1016/j.jtho.2021.02.009. Epub 2021 Feb 16. J Thorac Oncol. 2021. PMID: 33607312 Free article. Clinical Trial.
Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy.
Guven DC, Aksun MS, Sahin TK, Aktepe OH, Yildirim HC, Taban H, Ceylan F, Kertmen N, Arik Z, Dizdar O, Kilickap S, Aksoy S, Yalcin S, Erman M. Guven DC, et al. Among authors: erman m. Support Care Cancer. 2021 Sep;29(9):5417-5423. doi: 10.1007/s00520-021-06139-3. Epub 2021 Mar 11. Support Care Cancer. 2021. PMID: 33709186
270 results